...
首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >LINC00162 participates in the pathogenesis of diabetic nephropathy via modulating the miR-383/HDAC9 signalling pathway
【24h】

LINC00162 participates in the pathogenesis of diabetic nephropathy via modulating the miR-383/HDAC9 signalling pathway

机译:LINC00162通过调制MIR-383 / HDAC9信号通路参与糖尿病肾病发病机制

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Diabetic nephropathy (DN) is a common chronic complication of diabetes. In this study, we aimed to explore the potential role of lncRNA LINC-00162 in the pathogenic process of DN. LncRNA microarray analysis, real-time PCR, IHC computational analysis and luciferase assay were performed to explore the regulatory relationship among LINC00162, miR-383 and HDAC9. There was an obvious difference between T2D?+?DN and T2D???DN patients in their levels of eGRF and albuminuria. A significant difference was observed between T2D?+?DN and T2D???DN groups in terms of their LINC00162 expression. In particular, LINC00162 and HDAC9 were highly expressed, while miR-383 was lowly expressed in tissues derived from the T2D?+?DN group compared with those in tissues derived from the T2D???DN group. MiR-383 was able to bind to LINC00162, while HDAC9 was a direct downstream target of miR-383 with a complementary miR-383 binding site located in the 3′ UTR of HDAC9. LINC00162 reduced miR-383 expression and further up-regulated HDAC9 expression, while miR-383 mimics reduced HDAC9 expression under a dose-dependent manner. In summary, we suggested for the first time that down-regulation of LINC00162 was associated with the development of DN in T2D via the up-regulation of miR-383 expression and reduction of HDAC9 expression.
机译:糖尿病肾病(DN)是糖尿病的常见慢性并发症。在这项研究中,我们旨在探讨LNCRNA LINC-00162在DN的致病过程中的潜在作用。进行LNCRNA微阵列分析,实时PCR,IHC计算分析和荧光素酶测定以探讨LINC00162,MIR-383和HDAC9之间的调节关系。 T2D之间存在明显的差异?DN和T2D ??? DN患者的eGRF和白蛋白尿的水平。在其LIC00162表达方面,在T2D?+ + DN和T2D ??? DN组之间观察到显着差异。特别地,LINC00162和HDAC9高度表达,而MIR-383在与来自T2D衍生的组织中的组织中衍生自T2Dα+ DN组的组织中差别表达。 MiR-383能够与LINC00162结合,而HDAC9是miR-383的直接下游靶标,互补miR-383粘结位点位于HDAC9的3'UTR中。 LINC00162减少了MiR-383表达和进一步上调的HDAC9表达,而MiR-383以剂量依赖性方式模拟了HDAC9表达。总之,我们第一次建议LINC00162的下调通过MIR-383表达和HDAC9表达的上调和降低的HDAC9表达的调节与T2D中的DN开发有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号